Xilio Therapeutics, Inc.
No SEC Form 4 filings for $XLO in the last 30 days.
See all $XLO insider activity →Xilio Therapeutics, Inc. (XLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 xlo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancin
Xilio Therapeutics (Nasdaq: XLO) said it granted 107,060 non-qualified stock options to three new employees effective July 1, 2026 under its 2022 Inducement Stock Incentive Plan. Options have a $9.22 exercise price, 10-year term, and vest 25% after one year then 75% monthly over 36 months, subject to continued service.
Xilio Therapeutics, Inc. (XLO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001840233 0001840233 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10,
Over the past 7 days, alphai's AI scored 1 news story mentioning XLO (Xilio Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent XLO coverage spans financial news, corporate actions and earnings.
FDA IND clearance and a defined Phase 1 start window are the key near-term catalysts, alongside improved collaboration revenue and a cash runway into 1Q 2028.
Routine equity-compensation inducement grant; modest dilution/overhang risk but no new operating or clinical catalyst.
Board reclassification is largely governance/administrative, but the approved amended and restated 2021 Stock Incentive Plan (including evergreen share calculation for prefunded warrants) can affect future dilution expectations.
The appointment of a biotech veteran to Xilio Therapeutics' board may positively influence the company's strategic direction, potentially leading to increased investor confidence and a short-term uptick in stock price.
Positive clinical trial data for Xilio Therapeutics' Vilastobart may lead to increased investor confidence and potential stock appreciation.
alphai scores every news story that mentions XLO with an AI model for sentiment and relevance, and aggregates insider trades from Xilio Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Xilio Therapeutics, Inc. (XLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 xlo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancin
6 min readXilio Therapeutics (Nasdaq: XLO) said it granted 107,060 non-qualified stock options to three new employees effective July 1, 2026 under its 2022 Inducement Stock Incentive Plan. Options have a $9.22 exercise price, 10-year term, and vest 25% after one year then 75% monthly over 36 months, subject to continued service.
2 min readXilio Therapeutics, Inc. (XLO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001840233 0001840233 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10,
3 min readXilio Therapeutics (Nasdaq: XLO) has appointed Cheryl R. Blanchard, Ph.D., a biotech veteran with over 30 years of experience, to its board of directors, effective April 16, 2026. Dr. Blanchard's expertise in biologics, devices, and commercial strategy, including her current role as executive chair of Anika, is expected to support Xilio's masked immuno-oncology pipeline. This appointment follows the departure of Christina Rossi from the board on April 15, 2026.
2 min read40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden ...
3 min readPreclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index ...
3 min readWALTHAM, Mass., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Xilio Therapeutics, Inc. ( Nasdaq: XLO ) , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective November 1, 2025, the company ...
2 min readWALTHAM, Mass., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Xilio Therapeutics, Inc. ( Nasdaq: XLO ) , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will present a late-breaking poster ...
2 min readXilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting ...
3 min readWALTHAM, Mass., Oct. 02, 2025 ( GLOBE NEWSWIRE ) -- Xilio Therapeutics, Inc. ( Nasdaq: XLO ) , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2025, the company ...
2 min read
